KCNJ11: ATP-sensitive inward rectifier potassium channel 11
Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on KCNJ11, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Diazoxide | Approved | Merck & Co. (MSD) | Small molecule | OpenerPotassium channel, inwardly rectifying, subfamily J, member 11 opener | 5 |
| Diazoxide in the Treatment of Type 1 Glycogenosis | Diazoxide | — | Not yet recruiting | Central Hospital, Nancy, France | Jul 31, 2026 |
| Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome | Diazoxide | — | Enrolling by invitation | Soleno Therapeutics, Inc. | Mar 5, 2026 |
| Effect of Insulin Lowering on Lipogenesis | Diazoxide | Phase 1 | Recruiting | Columbia University | Feb 11, 2026 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | Diazoxide | — | Recruiting | Duke University | Feb 20, 2020 |
| Regulation of Endogenous Glucose Production by Central KATP Channels | Diazoxide | Phase 2 | Recruiting | Albert Einstein College of Medicine | May 30, 2018 |
- Type 2 diabetes mellitus0.88
- Hyperinsulinemic hypoglycemia, familial, 20.84
- Diabetes mellitus, permanent neonatal 20.81
- Diabetes mellitus, transient neonatal, 30.80
- Diabetes mellitus0.80
- Transient neonatal diabetes mellitus0.72
- Permanent neonatal diabetes mellitus0.71
- Maturity-onset diabetes of the young0.70
- Autosomal dominant hyperinsulinism due to Kir6.2 deficiency0.69
- Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency0.69
- Hypertensive disorder0.68
- Familial hyperinsulinism0.66
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1886, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14654, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets